Merck KGaA, of Darmstadt, Germany, said its biopharmaceutical unit, EMD Serono, entered a collaboration with Illumina Inc., of San Diego, to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies.